Current treatments and future targeted treatments for acute myeloid leukaemia

Eliza Vakana*, Jessica K. Altman, Leonidas C. Platanias

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


While the initial therapy for acute myeloid leukaemia (AML) treatment is relatively standardised, the high incidence of refractory/relapsed disease remains a great challenge. Progress has been made in understanding the pathophysiology of both initial and recurrent disease phases, leading to rigorous pre-clinical studies to identify and selectively target cellular pathways that promote leukaemogenesis. In this article, we discuss the ongoing efforts in overcoming relapsed disease, through a literature-based examination of primary papers and clinical trials, focusing on specific targets and their exploitation for future therapeutic development. The main focus of this article is to review therapies targeting CREB, Triad1, the BCL-2 family and JAK/STAT.

Original languageEnglish (US)
JournalClinical Pharmacist
Issue number3
StatePublished - Mar 2016


  • ABT-199
  • ASP2215
  • AZD1480
  • AZD9150
  • Acute myeloid leukaemia (AML)
  • BCL-2
  • CREB
  • JAK
  • Napthol AS-e
  • Navitoclax
  • Obatoclax
  • Ruxolitinib
  • STAT
  • Triad1

ASJC Scopus subject areas

  • Pharmacy
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Current treatments and future targeted treatments for acute myeloid leukaemia'. Together they form a unique fingerprint.

Cite this